NDAORALTABLET, EXTENDED RELEASE
Approved
Jul 2016
Lifecycle
Peak
Competitive Pressure
0/100
Data completeness
2/8 — Basic
Drug data last refreshed 7h ago · AI intelligence enriched 1w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
VIEKIRA XR is a fixed-dose combination oral tablet containing dasabuvir, ombitasvir, paritaprevir, and ritonavir approved in 2016 for hepatitis C virus (HCV) treatment. It is a direct-acting antiviral (DAA) regimen targeting multiple HCV non-structural proteins to achieve viral suppression. This extended-release formulation simplifies dosing for chronic HCV patients.
Peak8.5 years to LOE
Product is at peak lifecycle stage with stable established market presence; commercial teams are focused on market maintenance and optimization rather than growth expansion.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
Working on VIEKIRA XR offers stable, mature-market commercial experience in a well-established therapeutic area with predictable workflows and strong AbbVie infrastructure. This role is better suited for professionals seeking steady-state portfolio management and patient access optimization rather than product launch excitement or early-stage development challenges.
Brand Manager
Worked on VIEKIRA XR at AbbVie? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.